(Q27011165)

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

ChEBI ID

82717

Staphylococcus aureus

object named as

Staphylococcus aureus

1 reference

K. A. Rodvold

1

1 reference

K. W. McConeghy

series ordinal

2

1 reference

language of work or name

1 reference

January 2014

1 reference

Clinical Infectious Diseases

published in

1 reference

volume

58 Suppl 1

1 reference

page(s)

S20-7

1 reference

MRSA: the first half century

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

The oxazolidinones: past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

New treatments for methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Vancomycin: a 50-something-year-old antibiotic we still don't understand

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Vancomycin: we can't get there from here.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Linezolid, the first oxazolidinone antibacterial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

The emerging problem of linezolid-resistant Staphylococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Tigecycline: a novel broad-spectrum antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Efficacy and safety of tigecycline: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Excess deaths associated with tigecycline after approval based on noninferiority trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Summary of ceftaroline fosamil clinical trial studies and clinical safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Discovering new antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Antibiotics in development targeting protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614

The antibiotic R&D pipeline: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT614